The Discovery and Characterization of an Interleukin 6 Cytokine Family Antagonist Protein from A Marine Sponge, Callyspongia sp.
The process of drug discovery in the pharmaceutical industry often begins with the setting up of a bioassay whereby many thousands of synthetic compounds, or less characterized substances such as natural product extracts, may be screened in high throughput mode. During the early 1990s, we started a search using this approach for inhibitors of the cytokine Interleukin 6 (IL-6). One of the sources for screening was extracts of marine organisms provided to the former Ciba-Geigy organization by Harbor Branch Oceanographic Institute (HBOI). This chapter describes the finding of activity inhibiting IL-6 function from an extract of the marine sponge Callyspongia sp., and work which was carried out during the effort to characterize this activity more fully.
KeywordsHepG2 Cell Marine Sponge Sponge Extract Natural Product Extract Immunoglobulin Secreting Cell
Unable to display preview. Download preview PDF.
- 2.Hirano, T. 1992. Interleukin-6 and its relation to inflammation and disease. Clin. Immunol & Immunopathol. 62:860.Google Scholar
- 12.Pomponi, S.A. 1976. A cytological study of the Haliclonidae and the Calyspongiidae (Porifera, Desmospongiae, Haplosclerida). In: “Aspects of Sponge Biology”, Eds. F.W. Harrison and R.R. Cowden, Academic Press.Google Scholar
- 14.Yoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami. T„ Nakahata, T., Hirabayashi, T., Yoneda, Y., Tanaka, K., Wang, W.Z, Mori, C., Shiota, K., Yoshida, N. and Kishimoto, T. 1996. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. U.S.A. 93:407.PubMedCrossRefGoogle Scholar
- 15.Betz, U.A.K., Bloch, W., van den Broeck, M., Yoshida, K., Taga, T. Kishimoto, T., Addicks, K., Rajewsky, K. and Muller, W. 1998. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunolgocial, hepatic and pulmonary defects. J. Exp. Med. 188: 1955.Google Scholar
- 16.Yamamori, T. and Sarai, A. 1992. Coevolution of cytokine receptor families in the immune and nervous system. Neurosci. Res. 15: 151.Google Scholar
- 19.Brackenhoff, J.P.J., de Hon. F.D., Fontaine, V., ten Boekel, E., Schooltink, H., Rose-John, S., Heinrich, P.C., Content, J. and Aarden, L.A. 1994. Development of a human interleukin-6 receptor antagonist. J Biol. Chem. 269: 86.Google Scholar
- 20.Sporcno, E., Savino, R., Ciapponi, L., Paonessa, G., Cabibo, A., Lahm, A., Pulkki, K., Sun, R-X., Toniatti, C., Klein, B. and Cilikberto, G. 1996. Human Interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 87:4510.Google Scholar